The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the implications of the COAPT trial results, the significance of these findings, their potential impact on clinical practice, and what they mean for patients with secondary mitral regurgitation.
The abstract entitled ‘Transcatheter Edge-to-edge Repair Of Functional Mitral Regurgitation In Heart Failure: Final Five-year Results From The COAPT Trial‘ (Abstract number 405-12) was presented at ACC.23 Together With WCC (ACC.23/WCC) in New Orleans, 4–6 March 2023.
Questions:
- What were the aims, design and eligibility criteria of the COAPT trial? (0:15)
- What were the primary and secondary endpoints, and what were the key findings of the COAPT trial? (1:58)
- What implications do the long-term outcomes of the COAPT trial have for the use of mitral transcatheter edge-to-edge repair as a treatment option for functional mitral regurgitation (MR) in heart failure (HF) patients? (3:11)
- Looking ahead, what further research is needed to fully understand the role of transcatheter edge-to-edge repair in the management of functional MR in HF patients? (4:12)
Disclosures: Gregg Stone has received grant/research support from Abbott, and honoraria/honorarium from Abbott.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of ACC 2023
Access more content on heart failure and interventional cardiology
